ArticleFrontiers in neurology2026
A simplified Fazekas scale for efficient assessment of white matter hyperintensities.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: White matter hyperintensities (WMH) are key neuroimaging markers of cerebral small vessel disease (CSVD) and are associated with neuropsychiatric symptoms in older adults. Although the Fazekas visual rating scale is widely used in research, its clinical adoption remains limited. Therefore, we developed a simplified Fazekas visual rating scale (sFazekas) for overall WMH assessment to facilitate clinical application. Methods: We randomly selected 900 participants from three MRI scanners and evaluated the reliability and scoring efficiency of sFazekas versus the Fazekas scale. Then, all participants were grouped according to the sFazekas scores, and intergroup differences among the different scores were analyzed. Next, we examined correlations among the sFazekas, the Fazekas, and WMH volume. Finally, we explored associations between the sFazekas and vascular risk factors related to CSVD. Results: The sFazekas demonstrated excellent inter-rater reliability ( Conclusion: The simplified Fazekas visual rating scale (sFazekas) demonstrates reliability comparable to the conventional Fazekas scale, with the practical advantage of shorter scoring time, suggesting its potential utility in the clinical assessment of overall white matter hyperintensity burden in patients with cerebral small vessel disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.